

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/028730 A2

(51) International Patent Classification⁷: A61K 31/505,
31/425, A61P 43/00

[US/US]; 98 Primrose Drive, New Providence, NJ 07974
(US).

(21) International Application Number: PCT/EP02/10826

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date:
26 September 2002 (26.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/325,485 27 September 2001 (27.09.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(71) Applicant (*for AT only*): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

Published:
— without international search report and to be republished upon receipt of that report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): COHEN, David, Saul

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS

(57) Abstract: The present invention relates to a pharmaceutical composition, comprising (a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A reductase inhibitors; (iii) an anti-hypertensive agent; and (iv) a serotonin reuptake inhibitor (SSRI) or, in each case, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

WO 03/028730 A2

BEST AVAILABLE COPY


Combinations

The present invention relates to a combination, especially a pharmaceutical composition, comprising

- (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and
- (b) at least one active ingredient selected from the group consisting of
 - (i) an anti-diabetic agent;
 - (ii) HMG-Co-A reductase inhibitors;
 - (iii) an anti-hypertensive agent; and
 - (iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, a pharmaceutically acceptable salt thereof;
and a pharmaceutically acceptable carrier.

PDE5 inhibitors include compounds of formula



in free or salt form, where

- R^1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio,
 R^2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino,
 R^3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio,
 R^4 is hydrogen or alkyl,
 R^5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula - $N(R^6)R^7$, aryl optionally substituted by one or more substituents selected from halogen or

alkoxy, or heteroaryl having 5 or 6 ring atoms, attached through a ring carbon atom to the indicated carbon atom, and

R^6 and R^7 are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R^6 and R^7 is hydrogen and the other is acyl, or R^6 and R^7 together with the nitrogen atom to which they are attached denote a 5- or 6- membered heterocyclyl group.

"Alkyl" as used herein denotes straight chain or branched alkyl, which may be, for example, C_1 - C_{10} -alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, straight or branched pentyl, straight or branched hexyl, straight or branched heptyl, straight or branched octyl, straight or branched nonyl or straight or branched decyl. Preferably alkyl is C_1 - C_8 -alkyl.

"Alkoxy" as used herein denotes straight chain or branched alkoxy which may be, for example, C_1 - C_{10} -alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, straight or branched pentoxy, straight or branched hexyloxy, straight or branched heptyloxy, straight or branched octyloxy, straight or branched nonyloxy or straight or branched decyloxy. Preferably, alkoxy is C_1 - C_4 -alkoxy.

"Alkylthio" as used herein may be C_1 to C_{10} -alkylthio such as methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, sec-butylthio, isobutylthio, tert-butylthio, pentylthio, hexylthio, heptylthio, octylthio, nonylthio or decylthio. Preferably alkylthio is C_1 to C_4 -alkylthio.

"Alkenyl" as used herein means straight chain or branched alkenyl, which may be, for example, C_2 to C_{10} -alkenyl such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, or straight or branched pentenyl, hexenyl, heptenyl, octenyl, nonenyl or decenyl. Preferred alkenyl is C_2 to C_4 -alkenyl.

"Cycloalkylalkyl" as used herein denotes alkyl, for example C_1 to C_{10} -alkyl such as one of the C_1 to C_{10} -alkyl groups hereinbefore mentioned, substituted by a C_3 to C_8 cycloalkyl group such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclohexyl, dimethylcyclohexyl, cycloheptyl or cyclooctyl. Preferably, cycloalkylalkyl is C_3 - C_6 -cycloalkyl- C_1 - C_4 -alkyl.

"Heterocyclalkyl" as used herein denotes alkyl, for example C₁ to C₁₀-alkyl such as one of the C₁ to C₁₀-alkyl groups hereinbefore mentioned, substituted by a 5- or 6- membered heterocycl group having one or two hetero atoms selected from nitrogen, oxygen and sulfur in the ring, such as pyrrolyl, pyrrolidinyl, furyl, thienyl, pyridyl, piperidyl, imidazolyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, oxazolyl, or furazanyl. Preferably, heterocyclalkyl is C₁-C₄-alkyl substituted by a 5- or 6- membered heterocycl group having one or two nitrogen or oxygen atoms or one nitrogen atom and one oxygen atom in the ring.

"Aralkyl" as used herein means C₆-C₁₀-aryl-C₁-C₁₀ alkyl and may be, for example, one of the C₁-C₁₀-alkyl groups mentioned hereinbefore, particularly one of the C₁-C₄-alkyl groups, substituted by phenyl, tolyl, xyl or naphthyl. Preferably, aralkyl is phenyl-C₁-C₄-alkyl, particularly benzyl or 2-phenylethyl.

"Acyl" as used herein denotes alkylcarbonyl, for example C₁-C₁₀-alkylcarbonyl where C₁-C₁₀-alkyl may be one of the C₁-C₁₀-alkyl groups hereinbefore mentioned, optionally substituted by one or more halogen atoms; cycloalkylcarbonyl, for example C₃-C₈-cycloalkylcarbonyl where C₃-C₈-cycloalkyl may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; 5- or 6- membered heterocyclcarbonyl having one or two hetero atoms selected from nitrogen, oxygen and sulfur in the ring, such as furylcarbonyl or pyridylcarbonyl; arylcarbonyl, for example C₆-C₁₀-arylcarbonyl such as benzoyl; or aralkylcarbonyl, for example C₆ to C₁₀-aryl-C₁-C₄-alkylcarbonyl such as benzylcarbonyl or phenylethylcarbonyl. Preferably acyl is C₁-C₄-alkylcarbonyl.

"Alkynyl" as used herein denotes straight or branched alkynyl, for example C₂ to C₆-alkynyl such as ethynyl, propargyl, 2-butynyl, pentynyl or hexynyl. Preferably alkynyl is C₂-C₄-alkynyl.

"Aryl" as used herein denotes a monovalent carbocyclic aromatic group, for example C₆-C₁₀-aryl such as phenyl, phenyl substituted by one or more, e.g. one, two or three, C₁-C₄-alkyl groups, or naphthyl. Preferably aryl is phenyl.

"Heteroaryl having 5 or 6 ring atoms" as used herein denotes a monovalent aromatic heterocyclic group having 5 or 6 ring atoms of which one, two or three are selected from nitrogen, oxygen and sulfur, such as pyrrolyl, furyl, thienyl, pyridyl, pyrazolyl, imidazolyl,

triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, dithiazolyl, trithiazolyl, furazanyl, pyrazinyl, pyrimidinyl or triazinyl.

In alkylamino, dialkylamino, acylamino, dialkylaminosulfonylamino, alkylcarbonyl, alkylcarbonyloxy, alkoxy carbonyl, hydroxyalkyl, alkylthioalkyl and alkoxyalkyl, the alkyl, acyl or alkoxy groups as appropriate have the meanings hereinbefore described.


"Halogen" as used herein may be fluorine, chlorine, bromine or iodine; preferably it is fluorine, chlorine or bromine.

The 5- membered heterocyclic ring to which R^5 as a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group is optionally fused may be, for example, a 5- membered heterocyclic ring having one or two hetero atoms in the ring, said hetero atoms being selected from oxygen, nitrogen and sulfur. Examples of such heterocyclic rings include pyrrole, pyrrolidine, pyrrolidine, furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, dioxolane, oxazole, isoxazole, thiazole and isothiazole rings. Preferably the 5- membered heterocyclic ring is a saturated ring having two hetero atoms, preferably two oxygen or two nitrogen atoms, especially two oxygen atoms.


R^5 as a quinolinyl group may be a 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl or 8-quinolinyl group, preferably a 4-quinolinyl, 5-quinolinyl or 8-quinolinyl group. R^5 as an isoquinolinyl group may be a 1-isoquinolinyl, 3-isoquinolinyl, 4-isoquinolinyl, 5-isoquinolinyl, 6-isoquinolinyl, 7-isoquinolinyl, or 8-isoquinolinyl group, preferably a 1-isoquinolinyl or 4-isoquinolinyl group. In most of the especially preferred embodiments of the invention, R^5 is a 4-isoquinolinyl group.

R^5 as a substituted quinolinyl or isoquinolinyl group is preferably substituted by one, two, three or four of the abovementioned substituents, especially one, two or three of those substituents. The preferred substituted 4-isoquinolinyl group is preferably substituted in the 1- and/or 6- and/or 7- and/or 8- position of the isoquinoline ring system.

In especially preferred embodiments of the invention, R^5 is a quinolinyl group of formula




or an isoquinolinyl group of formula



where R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} are each independently hydrogen or a substituent selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula - $N(R^6)R^7$, aryl optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms, or R^{11} and R^{12} together with the carbon atoms to which they are attached denote a 5-membered heterocyclic group having two oxygen or nitrogen atoms in the ring, and R^6 and R^7 are as hereinbefore defined.

R^5 as an oxodihydroisoquinolinyl group preferably has the oxo group ortho to the ring nitrogen atom, preferably in the 1-position in the isoquinoline ring system. It is preferably linked to the remainder of the molecule of formula I via the ring carbon atom meta to the ring nitrogen atom, i.e. the 4-position in the isoquinoline ring system. An especially preferred oxodihydroisoquinolinyl group is of formula



where R^{10} , R^{11} , R^{12} and R^{13} are as hereinbefore defined and R^a is hydrogen or C_1 - C_4 -alkyl.

Preferred among the compounds of formula I in free or salt form are those where

R¹ is hydrogen or C₁-C₄-alkyl optionally substituted by hydroxy, C₁-C₄-alkoxy or C₁-C₄-alkylthio,

R² is hydrogen, C₁-C₈-alkyl, hydroxy-C₁-C₈-alkyl, C₁-C₄-alkylcarbonyloxy -C₁-C₈-alkyl, C₁-C₄-alkoxy -C₁-C₈-alkyl, C₁-C₄-alkylthio-C₁-C₈-alkyl, C₂-C₄-alkenyl, C₃-C₈-cycloalkyl-C₁-C₄-alkyl, heterocyclyl-C₁-C₄-alkyl where the heterocyclyl group is a 5- or 6- membered heterocyclyl group having one or two hetero atoms selected from nitrogen and oxygen atoms in the ring, phenyl-C₁-C₄-alkyl in which the phenyl ring is optionally substituted by one or more substituents selected from C₁-C₄-alkoxy, amino, C₁-C₄-alkylamino, di(C₁-C₄-alkyl)amino, C₁-C₄-alkylcarbonylamino, halogen, C₁-C₄-alkylsulfonylamino, or di(C₁-C₄-alkyl)aminosulfonylamino, and is optionally fused to a 5- membered heterocyclic ring having two oxygen or two nitrogen atoms in the ring,

R³ is hydrogen or C₁-C₄-alkyl optionally substituted by hydroxy, C₁-C₄-alkoxy or C₁-C₄-alkylthio,

R⁴ is hydrogen or C₁-C₄-alkyl,

R⁵ is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group having two oxygen or two nitrogen atoms in the ring and optionally substituted by one or more substituents selected from halogen, cyano, carboxy, hydroxy, C₁-C₄-alkyl, hydroxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-alkylcarbonyl, a group -N(R⁶)R⁷ or phenyl optionally substituted by one or more substituents selected from halogen or C₁-C₄-alkoxy and

R⁶ and R⁷ are each independently hydrogen or C₁-C₄-alkyl optionally substituted by hydroxy or alkoxy, or one of R⁶ and R⁷ is hydrogen and the other is C₁-C₄-alkylcarbonyl, or R⁶ and R⁷ together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclyl group having one or two nitrogen atoms and, optionally, an oxygen atom in the ring.

Further preferred among the compounds of formula I are those where

R¹ is hydrogen or C₁-C₄-alkyl, R² is hydrogen, C₁-C₈-alkyl, hydroxy -C₁-C₈-alkyl, or C₁-C₄-alkylcarbonyloxy-C₁-C₈-alkyl, C₂-C₄-alkenyl, C₃-C₈-cycloalkyl-C₁-C₄-alkyl, heterocyclyl-C₁-C₄-alkyl where the heterocyclyl group is a 5- membered heterocyclyl group having one nitrogen or oxygen atom in the ring, phenyl-C₁-C₄-alkyl in which the phenyl ring is optionally substituted by one or two substituents selected from C₁-C₄-alkoxy, amino, C₁-C₄-

alkylcarbonylamino, chlorine, bromine, C₁-C₄-alkylsulfonylamino, or di(C₁-C₄-alkyl)aminosulfonylamino and is optionally fused to a 5-membered heterocyclic ring having two oxygen atoms in the ring,

R³ is hydrogen or C₁-C₄-alkyl,

R⁴ is hydrogen or C₁-C₄-alkyl,

R⁵ is a quinolinyl group of formula II, an isoquinolinyl group of formula III or an oxodihydroisoquinolinyl group of formula IIIA, where R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ are each independently selected from hydrogen, halogen, cyano, carboxy, hydroxy, C₁-C₄-alkyl, hydroxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-alkylcarbonyl, a group -N(R⁶)R⁷ or phenyl optionally substituted by one or two substituents selected from halogen or C₁-C₄-alkoxy, or R¹¹ and R¹² together with the carbon atoms to which they are attached denote a 5-membered heterocyclic group having two oxygen atoms in the ring, and

R⁶ and R⁷ are each independently hydrogen or C₁-C₄-alkyl optionally substituted by hydroxy or alkoxy or one of R⁶ and R⁷ is hydrogen and the other is C₁-C₄-alkylcarbonyl, or R⁶ and R⁷ together with the nitrogen atom to which they are attached denote a 6-membered heterocyclyl group having one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, in the ring.

Amongst the further preferred compounds hereinbefore described, especially preferred compounds are usually those in which R⁵ is an isoquinolinyl group of formula III in which R⁸ is hydrogen, C₁-C₄-alkyl, halogen, cyano, -N(R⁶)R⁷ where R⁶ and R⁷ are independently C₁-C₄-alkyl or R⁶ and R⁷ together with the nitrogen atom to which they are attached denote a 6-membered heterocyclyl group having one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, in the ring, or phenyl substituted by one or two C₁-C₄-alkoxy groups; R⁹ and R¹⁰ are each independently hydrogen, C₁-C₄-alkyl or halogen; R¹¹ and R¹² are each independently hydrogen, halogen, cyano, carboxy, hydroxy, C₁-C₄-alkyl, C₁-C₄-alkoxy or C₂-C₄-alkynyl, or R¹¹ and R¹² together with the carbon atoms to which they are attached denote a 5-membered heterocycle having two oxygen atoms in the ring; and R¹³ is hydrogen or halogen.

Specific especially preferred compounds of formula I are those hereinafter described in the Examples. More preferred amongst these compounds are those of Examples 7, 10, 15, 35, 45, 49, 55, 60, 68 and 70.

According to the present invention preferred combinations are combinations of a PDE 5 inhibitor with an anti-diabetic agent, an anti-hypertensive agent or with both, an anti-diabetic agent and an anti-hypertensive agent, particularly with the active ingredients disclosed as preferred herein.

Especially preferred are combinations of the compound of Example 45 herein with an active ingredient selected from the group consisting of benazepril, benazepril and hydrochlorothiazide, valsartan, valsartan and hydrochlorothiazide, amlodipine, aliskiren, fluvastatin, pitavastatin, hydrochlorothiazide, the DPP IV inhibitors of example 3 of WO 98/19998 and Example 1 of WO 00/34241, respectively, nateglinide, repaglinide and metformin.


The term "at least one active ingredient" as used throughout this specification and in the claims means a combination of a PDE 5 inhibitor with one or more, preferably two or three, active ingredients from one or more, preferably two or three, groups of active ingredients.

Compounds of formula I may be in the form of salts, particularly pharmaceutically acceptable salts. Pharmaceutically acceptable acid addition salts of compounds of formula I include those of inorganic acids, for example, hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1-hydroxynaphthalene-2-carboxylic acid or 3-hydroxynaphthalene-2-carboxylic acid, and sulfonic acids such as methanesulfonic acid or benzenesulfonic acid. Pharmaceutically acceptable base salts of compounds of formula I where R³ is hydrogen include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, and salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared from free compounds of formula I or other salts of compounds of formula I by known salt-forming procedures.

PDE5 inhibitors also preferred in the context of the present invention are sildenafil, vardenafil and tadalafil or, in any case, in form of a pharmaceutically acceptable salt. Particularly preferred are PDE5 inhibitors that are marketed, e.g. VIAGRA® which is sildenafil citrate and which can be administered in this form.

Anti-diabetic agents include insulin secretion enhancers which are active ingredients that have the property to promote the secretion of insulin from pancreatic β -cells. Examples of insulin secretion enhancers are a biguanide derivative, for example, metformin or, if appropriate, a pharmaceutically acceptable salt thereof, especially the hydrochloride thereof. Other insulin secretion enhancers include sulfonylureas (SU), especially those which promote the secretion of insulin from pancreatic β -cells by transmitting signals of insulin secretion via SU receptors in the cell membrane, including (but are not limited to) tolbutamide; chlorpropamide; tolazamide; acetohexamide; 4-chloro-N-[(1-pyrrolidinylamino)carbonyl]-benzensulfonamide (glycopyramide); glibenclamide (glyburide); glipizide; 1-butyl-3-metanyllurea; carbutamide; glibonuride; glipizide; glipizide; glisoxepid; glybuthiazole; glibuzole; glyhexamide; glymidine; glypinamide; phenbutamide; and tolylcyclamide, or pharmaceutically acceptable salts thereof.

Insulin secretion enhancers furthermore include short-acting insulin secretion enhancers, such as the phenylalanine derivative nateglinide [N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine] (cf. EP 196222 and EP 526171) of the formula



and repaglinide [(S)-2-ethoxy-4-{2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl}benzoic acid]. Repaglinide is disclosed in EP 589874, EP 147850 A2, in particular Example 11 on page 61, and EP 207331 A1. It can be administered in the form as it is marketed, e.g. under the trademark NovoNorm™; calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)-propionate dihydrate (mitiglinide – cf. EP 507534); furthermore representatives of the new generation of SUs such as glimepiride (cf. EP 31058); in free or pharmaceutically acceptable salt form. The term nateglinide likewise comprises crystal modifications such as disclosed in EP 0526171 B1 or US 5,488,510, respectively, the subject matter of which, especially with respect to the identification,

manufacture and characterization of crystal modifications, is herewith incorporated by reference to this application, especially the subject matter of claims 8 to 10 of said U.S. patent (referring to H-form crystal modification) as well as the corresponding references to the B-type crystal modification in EP 196222 B1 the subject matter of which, especially with respect to the identification, manufacture and characterization of the B-form crystal modification. Preferably, in the present invention, the B- or H-type, more preferably the H-type, is used. Nateglinide can be administered in the form as it is marketed e.g. under the trademark STARLIX™.

Insulin secretion enhancers likewise include the long-acting insulin secretion enhancer DPP-IV inhibitors, GLP-1 and GLP-1 agonists.

DPP-IV is responsible for inactivating GLP-1. More particularly, DPP-IV generates a GLP-1 receptor antagonist and thereby shortens the physiological response to GLP-1. GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal.

The DPP-IV inhibitor can be peptidic or, preferably, non-peptidic. DPP-IV inhibitors are in each case generically and specifically disclosed e.g. in WO 98/19998, DE 196 16 486 A1, WO 00/34241 and WO 95/15309, in each case in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the pharmaceutical preparations and the claims are hereby incorporated into the present application by reference to these publications. Preferred are those compounds that are specifically disclosed in Example 3 of WO 98/19998 and Example 1 of WO 00/34241, respectively.

GLP-1 is a insulinotropic peptide which was described, e.g., by W.E. Schmidt et al. in Diabetologia 28, 1985, 704-707 and in US 5,705,483.

The term "GLP-1 agonists" used herein means variants and analogs of GLP-1(7-36)NH₂ which are disclosed in particular in US 5,120,712, US 5,118,666, US 5,512,549, WO 91/11457 and by C. Orskov et al in J. Biol. Chem. 264 (1989) 12826. The term "GLP-1 agonists" comprises especially compounds like GLP-1(7-37), in which compound the carboxy-terminal amide functionality of Arg³⁶ is displaced with Gly at the 37th position of the GLP-1(7-36)NH₂ molecule and variants and analogs thereof including GLN⁹-GLP-1(7-37),

D-GLN⁹-GLP-1(7-37), acetyl LYS⁹-GLP-1(7-37), LYS¹⁸-GLP-1(7-37) and, in particular, GLP-1(7-37)OH, VAL⁸-GLP-1(7-37), GLY⁸-GLP-1(7-37), THR⁸-GLP-1(7-37), MET⁸-GLP-1(7-37) and 4-imidazopropionyl-GLP-1. Special preference is also given to the GLP agonist analog exendin-4, described by Greig et al in *Diabetologia* 1999, 42, 45-50.

An insulin sensitivity enhancer restores impaired insulin receptor function to reduce insulin resistance and consequently enhance the insulin sensitivity.

An appropriate insulin sensitivity enhancer is, for example, an appropriate hypoglycemic thiazolidinedione derivative (glitazone).

An appropriate glitazone is, for example, (S)-((3,4-dihydro-2-(phenyl-methyl)-2H-1-benzopyran-6-yl)methyl-thiazolidine-2,4-dione (englitazone), 5-[[4-(3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl)-phenyl]-methyl]-thiazolidine-2,4-dione (darglitazone), 5-[[4-(1-methyl-cyclohexyl)methoxy]-phenyl]-methyl]-thiazolidine-2,4-dione (ciglitazone), 5-[[4-(2-(1-indolyl)ethoxy)phenyl]-methyl]-thiazolidine-2,4-dione (DRF2189), 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy]]benzyl}-thiazolidine-2,4-dione (BM-13.1246), 5-(2-naphthylsulfonyl)-thiazolidine-2,4-dione (AY-31637), bis{4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl}methane (YM268), 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy]benzyl}-thiazolidine-2,4-dione (AD-5075), 5-[4-(1-phenyl-1-cyclopropanecarbonylamino)-benzyl]-thiazolidine-2,4-dione (DN-108) 5-[[4-(2-(2,3-dihydroindol-1-yl)ethoxy)phenyl]-methyl]-thiazolidine-2,4-dione, 5-[3-(4-chloro-phenyl)]-2-propynyl]-5-phenylsulfonylthiazolidine-2,4-dione, 5-[3-(4-chlorophenyl)]-2-propynyl]-5-(4-fluorophenyl-sulfonyl)thiazolidine-2,4-dione, 5-[[4-(2-(methyl-2-pyridinyl-amino)-ethoxy)phenyl]-methyl]-thiazolidine-2,4-dione (rosiglitazone), 5-[[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]-methyl]thiazolidine-2,4-dione (pioglitazone), 5-[[4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)-phenyl]-methyl]-thiazolidine-2,4-dione (troglitazone), 5-[6-(2-fluoro-benzyloxy)naphthalen-2-ylmethyl]-thiazolidine-2,4-dione (MCC555), 5-[[2-(2-naphthyl)-benzoxazol-5-yl]-methyl]thiazolidine-2,4-dione (T-174) and 5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)benzamide (KRP297). Preferred are pioglitazone, rosiglitazone and troglitazone.

Other anti-diabetic agents include, insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), antidiabetic non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT);

compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK); pyruvate dehydrogenase kinase (PDHK) inhibitors; inhibitors of gastric emptying; insulin; inhibitors of GSK-3; retinoid X receptor (RXR) agonists; agonists of Beta-3 AR; agonists of uncoupling proteins (UCPs); non-glitazone type PPAR γ agonists; dual PPAR γ / PPAR α agonists; antidiabetic vanadium containing compounds; incretin hormones, like glucagon-like peptide-1 (GLP-1) and GLP-1 agonists; β -cell imidazoline receptor antagonists; miglitol; and α_2 -adrenergic antagonists; in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt.

The term "insulin signalling pathway modulators" as defined herein relates in particular to inhibitors of PTPase, antidiabetic non-small molecule mimetic compounds and inhibitors of GFAT.

Examples of "inhibitors of PTPase" include, but are not limited to those disclosed in U.S. Patent No. 6,057,316, U.S. Patent No. 6,001,867, WO 99/58518, WO 99/58522, WO 99/46268, WO 99/46267, WO 99/46244, WO 99/46237, WO 99/46236, WO 99/15529 and by Poucheret et al in Mol. Cell Biochem. 1998, 188, 73-80.

The term "antidiabetic non-small molecule mimetic compounds" as defined herein means compounds as disclosed in Science 1999, 284; 974-97, especially L-783,281, and WO 99/58127, especially CLX-901.

Examples of "inhibitors of GFAT" include, but are not limited to those disclosed in Mol. Cell. Endocrinol. 1997, 135(1), 67-77.

The term "compounds influencing a dysregulated hepatic glucose production" as defined herein relates in particular to inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK).

The term "inhibitors of G6Pase" used herein means a compound or composition which reduces or inhibits hepatic gluconeogenesis by decreasing or inhibiting the activity of G6Pase. Examples of such compounds are disclosed in WO 00/14090, WO 99/40062, WO 98/40385, EP682024 and Diabetes 1998, 47, 1630-1636.

The term "inhibitors of F-1,6-BPase" used herein means a compound or composition which reduces or inhibits hepatic gluconeogenesis by decreasing or inhibiting the activity of F-1,6-BPase. Examples of such compounds are disclosed in WO 00/14095, WO 99/47549, WO 98/39344, WO 98/39343 and WO 98/39342.

The term "inhibitors of GP" as used herein means a compound or composition which reduces or inhibits hepatic glycogenolysis by decreasing or inhibiting the activity of GP. Examples of such compounds are disclosed in EP 978279, US Patent No. 5998463, WO 99/26659, EP 846464, WO 97/31901, WO 96/39384, WO9639385 and in particular CP-91149 as described in Proc. Natl. Acad Sci USA 1998, 95, 1776-1781.

The term "glucagon receptor antagonists" as used herein relates in particular to the compounds described in WO 98/04528, especially BAY27-9955, and those described in Bioorg Med. Chem. Lett 1992, 2, 915-918, especially CP-99,711, J. Med. Chem. 1998, 41, 5150-5157, especially NNC 92-1687, and J. Biol Chem. 1999, 274; 8694-8697, especially L-168,049 and compounds disclosed in US 5,880,139, WO 99/01423, US 5,776,954, WO 98/22109, WO 98/22108, WO 98/21957 and WO 97/16442.

The term "inhibitors of PEPCK" used herein means a compound or composition which reduces or inhibits hepatic gluconeogenesis by decreasing or inhibiting the activity of PEPCK. Examples of such compounds are disclosed in U.S. Patent No. 6,030,837 and Mol. Biol. Diabetes 1994, 2, 283-99.

The term "PDHK inhibitors" as used herein means inhibitors of pyruvate dehydrogenase kinase and include, but are not limited to, those compounds disclosed by Aicher et al in J. Med. Chem. 42 (1999) 2741-2746.

Examples of "inhibitors of gastric emptying" other than GLP-1 include, but are not limited to those disclosed in J. Clin. Endocrinol. Metab. 2000, 85(3), 1043-1048, especially CCK-8, and in Diabetes Care 1998; 21; 897-893, especially Amylin and analogs thereof, e.g.

Pramlintide. Amylin is also described e.g. by O.G. Kolterman et al. in *Diabetologia* 39, 1996, 492-499.

Insulin is available from different providers under different tradenames, e.g. Berlinsulin® (Berlin-Chemie), Huminsulin® (Eli Lilly), Insulin Actrapid® (Novo Nordisk) or Insuman® (Aventis).

Examples of "inhibitors of GSK-3" include, but are not limited to those disclosed in WO 00/21927 and WO 97/41854.

By "RXR agonist" is meant a compound or composition which when combined with RXR homodimers or heterodimers increases the transcriptional regulation activity of RXR, as measured by an assay known to one skilled in the art, including, but not limited to, the "co-transfection" or "cis-trans" assays described or disclosed in U.S. Pat. Nos. 4,981,784, 5,071,773, 5,298,429, 5,506,102, WO89/05355, WO91/06677, WO92/05447, WO93/11235, WO95/18380, PCT/US93/04399, PCT/US94/03795 and CA 2,034,220, which are incorporated by reference herein. It includes, but is not limited to, compounds that preferentially activate RXR over RAR (i.e. RXR specific agonists), and compounds that activate both RXR and RAR (i.e. pan agonists). It also includes compounds that activate RXR in a certain cellular context but not others (i.e. partial agonists). Compounds disclosed or described in the following articles, patents and patent applications which have RXR agonist activity are incorporated by reference herein: U.S. Pat. Nos. 5,399,586 and 5,466,861, WO96/05165, PCT/US95/16842, PCT/US95/16695, PCT/US93/10094, WO94/15901, PCT/US92/11214, WO93/11755, PCT/US93/10166, PCT/US93/10204, WO94/15902, PCT/US93/03944, WO93/21146, provisional applications 60,004,897 and 60,009,884, Boehm, et al. *J. Med. Chem.* 38(16):3146-3155, 1994, Boehm, et al. *J. Med. Chem.* 37(18):2930-2941, 1994, Antras et al., *J. Biol. Chem.* 266:1157-1161 (1991), Salazar-Olivo et al., *Biochem. Biophys. Res. Commun.* 204:157-263 (1994) and Safanova, *Mol. Cell. Endocrin.* 104:201-211 (1994). RXR specific agonists include, but are not limited to, LG 100268 (i.e. 2-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl]-pyridine-5-carboxylic acid) and LGD 1069 (i.e. 4-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-carbonyl]-benzoic acid), and analogs, derivatives and pharmaceutically acceptable salts thereof. The structures and syntheses of LG 100268 and LGD 1069 are disclosed in Boehm, et al. *J. Med. Chem.* 38(16):3146-3155, 1994, incorporated by reference herein. Pan agonists include, but are not limited to, ALRT 1057


(i.e. 9-cis retinoic acid), and analogs, derivatives and pharmaceutically acceptable salts thereof.

Examples of "agonists of Beta-3 AR" include, but are not limited to CL-316,243 (Lederle Laboratories) and those disclosed in WO 99/29672, WO 98/32753, WO 98/20005, WO 98/09625, WO 97/46556, WO 97/37646 and U.S. Patent No. 5,705,515.

The term "agonists of UCPs" used herein means agonists of UCP-1, preferably UCP-2 and even more preferably UCP-3. UCPs are disclosed in Vidal-Puig et al., *Biochem. Biophys. Res. Commun.*, Vol. 235(1) pp. 79-82 (1997). Such agonists are a compound or composition which increases the activity of UCPs.

"Non-glitazone type PPAR γ agonists" are especially N-(2-benzoylphenyl)-L-tyrosine analogues, e.g. GI-262570, and JTT501.

The term "dual PPAR γ /PPAR α agonists" as used herein means compounds which are at the same time PPAR γ and PPAR α agonists. Preferred dual PPAR γ /PPAR α agonists are especially those ω -[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs thereof, the compound NN622 described in U.S. Patent 6,054,453, example 22; very especially the compound DRF-554158, also designated DRF 4158, described in WO 99/20614 having the following structure



and the compound NC-2100 described by Fukui in *Diabetes* 2000, 49(5), 759-767.

Preferably, the "antidiabetic vanadium containing compound" is a physiologically tolerable vanadium complex of a bidentate monoprotic chelant, wherein said chelant is an α -hydroxypyrrone or α -hydroxypyridinone, especially those disclosed in the Examples of US

5,866,563, of which the working examples are hereby incorporated by reference, or a pharmaceutically acceptable salt thereof.

The term "incretin hormones" as used herein relates in particular to glucagon-like peptide-1 (GLP-1) or GLP-1 agonists.

The term " β -cell imidazoline receptor antagonists" as used herein means compounds as those described in WO 00/78726 and by Wang et al in J. Pharmacol. Exp. Ther. 1996; 278; 82-89, e.g. PMS 812.

Miglitol is (2*R*, 3*R*, 4*R*, 5*S*)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol and is described in US 4,639,436. The 1-deoxynojirimycin derivative miglitol can be administered in the form as it is marketed e.g. under the trademark DIASTABOL 50™.

Examples of " α_2 -adrenergic antagonists" include, but are not limited to midaglizole described in Diabetes 36, 1987, 216-220.

The insulin signalling pathway modulators, compounds influencing a dysregulated hepatic glucose production, pyruvate dehydrogenase kinase (PDHK) inhibitors, inhibitors of gastric emptying, inhibitors of GSK-3, retinoid X receptor (RXR) agonists, agonists of Beta-3 AR, agonists of UCPs, non-glitazone type PPAR γ agonists, dual PPAR γ /PPAR α agonists, antidiabetic vanadium containing compounds, incretin hormones, β -cell imidazoline receptor antagonists, miglitol, and α_2 -adrenergic antagonists are in each case generically and specifically disclosed in the documents cited above, in each case in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the pharmaceutical preparations and the claims are hereby incorporated into the present application by reference to these publications. Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein and, where applicable, all pharmaceutically acceptable salts thereof.

Any person skilled in the art is fully enabled to identify the active agents and, based on the cited references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both *in vitro* and *in vivo*.

HMG-Co-A reductase inhibitors (also called β -hydroxy- β -methylglutaryl-co-enzyme-A reductase inhibitors) are understood to be those active agents that may be used to lower the lipid levels including cholesterol, especially LDL-cholesterol, in blood.

The class of HMG-Co-A reductase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds that are selected from the group consisting of atorvastatin (cf. EP 680320), cerivastatin (cf. EP 491226), fluvastatin (cf. US 5354772), pitavastatin (cf. EP 304063), lovastatin (cf. EP 22478), pravastatin (cf. UK 2077264), rosuvastatin (S 4522) (Wantanabe M., Bioorganic and Medicinal Chemistry (1997) Vol. 5(2) pp. 437-444) and simvastatin (cf. EP 33538), or, in each case, a pharmaceutically acceptable salt thereof.

Preferred HMG-Co-A reductase inhibitors are those agents that have been marketed, most preferred is fluvastatin, atorvastatin, pravastatin, or simvastatin and also pitavastatin or, in each case, a pharmaceutically acceptable salt thereof.


Anti-hypertensive agents include angiotensin converting enzyme inhibitors (ACE-inhibitors) and AT₁ receptor antagonists. The interruption of the enzymatic degradation of angiotensin I to angiotensin II with ACE-inhibitors is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of congestive heart failure.

The class of ACE inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting of alacepril (cf. EP 7477), benazepril (cf. EP 72352), benazeprilat (cf. EP 72352), captopril (cf. US 4105776), ceronapril (cf. EP 229520), cilazapril (cf. EP 94095), delapril (cf. EP 51391), enalapril (cf. EP 12401), enaprilat (cf. EP 12401), fosinopril (cf. EP 53902), imidapril (cf. EP 95163), lisinopril (cf. EP 12401), moveltipril (cf. ZA 82/3779), perindopril (cf. EP 49658), quinapril (cf. EP 49605), ramipril (cf. EP 79022), spirapril (cf. EP 50800), temocapril (cf. EP 161801), andtrandolapril (cf. EP 551927), or, in each case, a pharmaceutically acceptable salt thereof.


Preferred ACE inhibitors are those agents that have been marketed, most preferred are benazepril, enalapril and lisinopril.

The corresponding active ingredients or pharmaceutically acceptable salts thereof may also be used in form of a solvate, such as a hydrate or including other solvents, used for crystallization.


The class of AT₁ receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. For example, mention may be made of the compounds which are selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, the compound with the designation E-1477 of the following formula



the compound with the designation SC-52458 of the following formula



and the compound with the designation the compound ZD-8731 of the following formula



or, in each case, a pharmaceutically acceptable salt thereof.

Preferred AT₁-receptor antagonist are those agents which have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.

Anti-hypertensive agents also include renin inhibitors. Renin inhibitors include especially non-peptidic representatives, preferably aliskiren (2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, being specifically disclosed in EP 678503 A); especially preferred is the hemi-fumarate salt thereof; detikiren (cf. EP 173481A); terlakiren (cf. EP 266950 A); and zankiren (cf. EP 229667 A). Especially preferred is aliskiren, preferably the hemi-fumarate thereof.

Additional anti-hypertensive agents include adrenergic blockers, diuretics, e.g. hydrochlorothiazide, neutral endo-peptidases inhibitors, endothelin converting enzyme inhibitors, endothelin receptor antagonists, adrenergic stimulants, alpha/beta adrenergic blockers beta adrenergic blocking agents, calcium channel blockers, rauwolfia derivatives and vasodilators or any combination thereof.

Adrenergic blockers include propranolol, bisoprolol and metoprolol.

Examples of calcium channel blockers useful in the combinations of the present invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, verapamil, gallopamil and tiapamil or in each case a pharmaceutically acceptable salt thereof.

Preferred calcium channel blockers are those which are marketed, especially amlodipine.

Serotonin reuptake inhibitors (SSRIs), include, for example, fluvoxamine; fluoxetine; paroxetine; sertraline; citalopram; venlafaxine; cericlamine; duloxetine; milnacipran; nefazodone; and cyanodothiepin (*See The Year Drugs News*, 1995 Edition, pp. 47-48 by Prous J.R.) and WO 97/29739.


The compounds to be combined can be present as pharmaceutically acceptable salts. If these compounds have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds having an acid group (for example COOH) can also form salts with bases.

The structure of the active agents identified by generic or tradenames may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.

The following Examples further illustrate the invention with respect to specific PDE5 inhibitors. The preparation of the compounds of these Examples, their intermediates and their analytical characterization is disclosed in WO 01/77110, the whole content of which is being incorporated by reference herewith.






Examples 1- 87








Compounds of formula I which are also of formula









V







where R¹ to R⁴ and R⁸ to R¹³ are as hereinbefore defined, in free or salt form, and their methods of preparation are shown in the following table, the methods being described hereinafter. R³ is H in all Examples except No 44, where it is CH₃. R⁴ is H in all examples except Nos 25 - 27 and 41 - 43, where it is CH₃. R⁹ is H in all Examples except No 29, where it is CH₃. R¹⁰ is H in all Examples except No 57, where it is Br and No 75 where it is Cl. R¹³ is H in all Examples except Nos 56 where it is F, and 65 and 66, where it is Br.





Ex. No.	R ¹	R ²	R ⁸	R ¹¹	R ¹²
1	CH ₃	(CH ₃) ₂ CHCH ₂		OCH ₃	OCH ₃
2	CH ₃	(CH ₃) ₂ CHCH ₂		OCH ₃	OCH ₃
3	CH ₃	(CH ₃) ₂ CHCH ₂		OCH(CH ₃) ₂	OCH ₃
4	CH ₃	(CH ₃) ₂ CHCH ₂		OCH(CH ₃) ₂	OCH ₃
5	CH ₃	(CH ₃) ₂ CHCH ₂	(CH ₃) ₃ C	OCH(CH ₃) ₂	OCH ₃
6	CH ₃	(CH ₃) ₂ CHCH ₂	(CH ₃) ₂ CH	OCH(CH ₃) ₂	OCH ₃
7	CH ₃	(CH ₃) ₂ CHCH ₂	CH ₃	OCH ₃	OCH ₃
8	CH ₃	(CH ₃) ₂ CHCH ₂	(CH ₃) ₃ C	OCH ₃	OCH ₃
9	CH ₃	(CH ₃) ₂ CHCH ₂	(CH ₃) ₂ CH	OCH ₃	OCH ₃
10	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₃
11	CH ₃		H	OCH ₃	OCH ₃
12	H	CH ₃	H	OCH ₃	OCH ₃
13	CH ₃	CH ₂ =CHCH ₂	H	OCH ₃	OCH ₃

Ex. No.	R ¹	R ²	R ⁸	R ¹¹	R ¹²
14	CH ₃		H	OCH ₃	OCH ₃
15	CH ₃	(CH ₃) ₃ CCH ₂	H	OCH ₃	OCH ₃
16	(CH ₃) ₂ CHCH ₂	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₃
17	CH ₃		H	OCH ₃	OCH ₃
18	CH ₃	CH ₂ =C(CH ₃)CH ₂	H	OCH ₃	OCH ₃
19	CH ₃		H	OCH ₃	OCH ₃
20	CH ₃		H	OCH ₃	OCH ₃
21	H	CH ₃ CH ₂ CH ₂	H	OCH ₃	OCH ₃
22	CH ₃		H	OCH ₃	OCH ₃
23	CH ₃	(CH ₃) ₂ CHCH ₂	H		
24	CH ₃	(CH ₃) ₂ CHCH ₂	H	H	OCH ₃
25	CH ₃	(CH ₃) ₂ CHCH ₂	Cl	H	OCH ₃
26	CH ₃	(CH ₃) ₂ CHCH ₂	CN	H	OCH ₃
27	CH ₃	(CH ₃) ₂ CHCH ₂		H	OCH ₃
28	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OH
29	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₃
30	CH ₃	CH ₃ (CH ₂) ₅	H	OCH ₃	OCH ₃

Ex. No.	R ¹	R ²	R ³	R ¹¹	R ¹²
31	CH ₃		H	OCH ₃	OCH ₃
32	CH ₃		H	OCH ₃	OCH ₃
33	CH ₃		H	OCH ₃	OCH ₃
34	CH ₃		H	OCH ₃	OCH ₃
35	CH ₃	(CH ₃) ₂ CHCH ₂	Cl	OCH ₃	OCH ₃
36	CH ₃	(CH ₃) ₂ CHCH ₂	H	H	H
37	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₂ CH ₃	OCH ₃
38	CH ₃	(CH ₃) ₂ CHCH ₂		OCH ₃	OCH ₃
39	CH ₃	(CH ₃) ₂ CHCH ₂		OCH ₃	OCH ₃
40	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₂ CH ₃
41	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₂ CH ₃	OCH ₃
42	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₂ CH ₃
43	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₃
44	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	OCH ₃
45	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	H

Ex. No.	R ^I	R ²	R ⁸	R ¹¹	R ¹²
46	CH ₃		H	OCH ₃	H
47	CH ₃	(CH ₃) ₃ CCH ₂	H	Cl	H
48	CH ₃	(CH ₃) ₂ CHCH ₂	H	Cl	H
49	CH ₃		H	OCH ₃	H
50	CH ₃		H	Cl	H
51	CH ₃		H	OCH ₃	OCH ₃
52	CH ₃	CH ₂ =C(CH ₃)CH ₂	H	OCH ₃	H
53	CH ₃	(CH ₃) ₂ CHCH ₂	H	Br	H
54	CH ₃	(CH ₃) ₃ CCH ₂	H	OCH ₃	H
55	CH ₃	(CH ₃) ₂ CHCH ₂	H	C≡CH	H
56	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	H
57	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	H
58	CH ₃		H	OCH ₃	OCH ₃
59	CH ₃		H	OCH ₃	OCH ₃
60	CH ₃		H	OCH ₃	OCH ₃
61	CH ₃		H	OCH ₃	OCH ₃

Ex. No.	R ¹	R ²	R ⁸	R ¹¹	R ¹²
62	CH ₃		H	OCH ₃	OCH ₃
63	CH ₃	(CH ₃) ₂ CHCH ₂	H	H	OH
64	CH ₃	(CH ₃) ₂ CHCH ₂	H	OH	OH
65	CH ₃	(CH ₃) ₂ CHCH ₂	H	OH	OH
66	CH ₃	(CH ₃) ₂ CHCH ₂	H	H	OH
67	CH ₃	HO(CH ₂) ₃	H	OCH ₃	OCH ₃
68	CH ₃		H	OCH ₃	OCH ₃
69	CH ₃		H	OCH ₃	OCH ₃
70	CH ₃		H	OCH ₃	OCH ₃
71	CH ₃		H	OCH ₃	H
72	CH ₃		H	OCH ₃	H
73	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	F
74	CH ₃	(CH ₃) ₂ CHCH ₂	H	CO ₂ H	H
75	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₃	H
76	CH ₃	(CH ₃) ₂ CHCH ₂	H	CN	H
77	CH ₃	(CH ₃) ₂ CHCH ₂	H	CH ₂ CH ₃	H
78	CH ₃	(CH ₃) ₂ CHCH ₂	H	OCH ₂ CH ₃	H

Ex. No.	R ¹	R ²	R ⁸	R ¹¹	R ¹²
79	CH ₃		H	OCH ₃	H
80	CH ₃		H	OCH ₃	H
81	CH ₃		H	OCH ₃	H
82	CH ₃	(CH ₃) ₂ CHCH ₂	N(CH ₂) ₃	OCH ₃	OCH ₃
83	CH ₃	(CH ₃) ₂ CHCH ₂		OCH ₃	OCH ₃
83	CH ₃	(CH ₃) ₂ CHCH ₂	CH ₃	OCH ₃	H
84	CH ₃	(CH ₃) ₂ CHCH ₂	CH ₃	OCH(CH ₃) ₂	H
85	CH ₃	(CH ₃) ₂ CHCH ₂	CH ₃	OCH ₂ CH ₃	H

Example 86 - 3-Isobutyl-1-methyl-8-[1-(6-methyl-5-oxo-5,6-dihydro-[1,3]dioxolo[4,5-g.]isoquinolin-8-yl)-ethyl]-3,7-dihydro-purine-2,6-dione

Example 87 - 8-(6,7-Dimethoxy-quinolin-4-ylmethyl)-3-isobutyl-1-methyl-3,7-dihydro-purine-2,6-dione

Another aspect of the present invention relates to the prevention, delay of progression or treatment of a condition or disease selected from the group consisting of sexual dysfunction, a cardiovascular disease or disorder, a diabetic disease or disorder, a hyperlipidemic disease or disorder, and a metabolic disease or disorder comprising administration of a therapeutically effective amount of a pharmaceutical composition comprising

(a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and

- (b) at least one active ingredient selected from the group consisting of
- (i) an anti-diabetic agent;
 - (ii) HMG-Co-A reductase inhibitors;
 - (iii) an anti-hypertensive agent; and
 - (iv) a serotonin reuptake inhibitor (SSRI)
- or, in each case, a pharmaceutically acceptable salt thereof;
- to a warm-blooded mammal in need thereof.

Another aspect of the present invention relates to the treatment of sexual dysfunction, especially male erectile dysfunction (MED) and a cardiovascular disease or disorder comprising administration of a therapeutically effective amount of a pharmaceutical composition comprising a PDE5 inhibitor and an anti-hypertensive agent to a warm-blooded mammal in need thereof. To evaluate the antihypertensive activity of the combination according to the invention, for example, the methodology as described by Lovenberg W: Animal models for hypertension research. Prog. Clin. Biol. Res. 1987, 229, 225-240 may be applied. For the evaluation that the combination according to the present invention may be used for the treatment of congestive heart failure, for example, the methods as disclosed by Smith HJ, Nuttall A: Experimental models of heart failure. Cardiovasc Res 1985, 19, 181-186 may be applied. Molecular approaches such as transgenic methods are also described, for example by Luft et al.: Hypertension-induced end-organ damage. A new transgenic approach for an old problem. Hypertension 1999, 33, 212-218.

Another aspect of the present invention relates to the treatment of MED and a diabetic disease or disorder comprising administration of a therapeutically effective amount of a pharmaceutical composition comprising a PDE5 inhibitor and an anti-diabetic agent to a warm-blooded mammal in need thereof. The insulin secretion enhancing properties of the combination according to the present invention may be determined by following the methodology as disclosed, for example, in the publication of Tilkenou et al. Biol.Pharm.Bull. 29(4), 354-359 (1997).

Another aspect of the present invention relates to the treatment of MED and a hyperlipidemic disease or disorder comprising administration of a therapeutically effective amount of a pharmaceutical composition comprising a PDE5 inhibitor and an HMG-CoA reductase inhibitor to a warm-blooded mammal in need thereof. To evaluate the HMG-Co-A reductase

inhibitory activities of the combination according to the invention, for example, may be determined by following the methodology as disclosed, for example, in US 4,739,073 or US 5,354,772, respectively. The corresponding subject matter of these two references is herewith incorporated by reference in this specification.

In yet another aspect of the present invention relates to the treatment of MED and a metabolic disease or disorder comprising administration of a therapeutically effective amount of a pharmaceutical composition comprising a PDE5 inhibitor and an SSRI to a warm-blooded mammal in need thereof.

The pharmaceutical activities as effected by administration of the combination of active agents used according to the present invention can be demonstrated e.g. by using corresponding pharmacological models known in the pertinent art. The person skilled in the pertinent art is fully enabled to select a relevant animal test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects.

Accordingly, the combination or pharmaceutical composition according to the present invention may be used, e.g., for the prevention, delay of progression or treatment of diseases and disorders selected from those named hereinbefore and hereinafter.

A "cardiovascular disease or disorder" as defined in this application comprises, but is not limited to hypertension, congestive heart failure, diabetes, glomerulosclerosis, chronic and acute renal failure, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis endothelial dysfunction, impaired vascular compliance and congestive heart failure.

A "diabetic disease or disorder" as defined in this application comprises, but is not limited to hyperglycemia, hyperinsulinaemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy and syndrome X.

A "hyperlipidemic disease or disorder" as defined in this application comprises, but is not limited to hyperlipidaemia, hypertriglyceridemia, coronary heart disease, vascular restenosis, endothelial dysfunction, obesity and impaired vascular compliance.

A "metabolic disease or disorder" as defined in this application comprises, but is not limited to obesity.

Hypertension, especially in connection with a "cardiovascular disease or condition", includes and is not limited to mild, moderate and severe hypertension as defined in Journal of Hypertension 1999, 17:151-183, especially on page 162. Especially preferred is "isolated systolic hypertension" (ISH).

Preferably, the jointly therapeutically effective amounts of the active agents according to the combination of the present invention can be administered simultaneously or sequentially in any order, e.g. separately or in a fixed combination.

All the more surprising is the experimental finding that the combined administration of a PDE5 inhibitor with an anti-diabetic agent, a HMG-Co A reductase inhibitor, an anti-hypertensive agent and/or an SSRI, in each case, a pharmaceutically acceptable form thereof, results not only in a beneficial, especially a potentiating or a synergistic, therapeutic effect. Independent thereof, additional benefits resulting from combined treatment can be achieved such as a surprising prolongation of efficacy, a broader variety of therapeutic treatment and surprising beneficial effects on diseases and conditions.

The term "potentiation" shall mean an increase of a corresponding pharmacological activity or therapeutic effect, respectively. Potentiation of one component of the combination according to the present invention by co-administration of an other component according to the present invention means that an effect is being achieved that is greater than that achieved with one component alone.

The term "synergistic" shall mean that the drugs, when taken together, produce a total joint effect that is greater than the sum of the effects of each drug when taken alone.

Further benefits are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.

The present invention also relates to a method for the prevention, delay of progression or treatment of sexual dysfunction, especially MED, and a diabetic, cardiovascular, metabolic, hyperlipidemic disease and disorder comprising administering to a warm-blooded mammal, including man, in need thereof jointly therapeutically effective amounts of a pharmaceutical composition comprising

- (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and
- (b) at least one active ingredient selected from the group consisting of
 - (i) an anti-diabetic agent;
 - (ii) HMG-Co-A reductase inhibitors;
 - (v) an anti-hypertensive agent; and
 - (vi) a serotonin reuptake inhibitor (SSRI)or, in each case, a pharmaceutically acceptable salt thereof;
and a pharmaceutically acceptable carrier.

Further, the present invention relates to the use of a combination comprising

- (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and
- (b) at least one active ingredient selected from the group consisting of
 - (i) an anti-diabetic agent;
 - (ii) HMG-Co-A reductase inhibitors;
 - (vii) an anti-hypertensive agent; and
 - (viii) a serotonin reuptake inhibitor (SSRI)or, in each case, a pharmaceutically acceptable salt thereof;

for the preparation of an agent for the treatment of sexual dysfunction, especially MED, a diabetic, cardiovascular, metabolic or hyperlipidemic disease and disorder.

The pharmaceutical composition according to the present invention as described hereinbefore and hereinafter may be used for simultaneous use or sequential use in any order, e.g. for separate use or as a fixed combination.

The pharmaceutical composition according to the present invention comprises a "kit of parts" in the sense that the components can be dosed independently or by use of different fixed combinations with distinguished amounts of the components at different time points. The parts of the "kit of parts" can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the "kit of parts". Preferably, the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is larger than the effect that would be obtained by use of only any one of the components. Preferably, there is at least one beneficial effect, e.g. a mutual enhancing of the effect of a pharmaceutical composition comprising

- (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and
- (b) at least one active ingredient selected from the group consisting of
 - (i) an anti-diabetic agent;
 - (ii) HMG-Co-A reductase inhibitors;
 - (iii) an anti-hypertensive agent; and
 - (iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable carrier;

in particular a potentiation or a synergism, e.g. a more than additive effect, additional advantageous effects, less side effects, a combined therapeutical effect in a non-effective dosage of one or each of the components, especially a potentiation or synergism.

The invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.

These pharmaceutical preparations are for oral administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compounds. These are prepared in a manner that is known per se, for example using conventional mixing, granulation, coating, solubilizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining

the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those that are commercially available.

Normally, in the case of oral administration of pharmaceutical composition in accordance with the present invention, an approximate daily dose of from about 1 mg to about 360 mg is to be estimated, preferably a daily dose of from 1 mg to 100 mg, more preferably a daily dose of from 1 mg to 50 mg, e.g. for a patient of approximately 75 kg in weight.

The insulin secretion enhancer repaglinde is preferably administered in a dosage range of about 0.01 mg to about 8 mg, more preferred from about 0.5 to about 6 mg.

In case of HMG-Co-A reductase inhibitors, preferred dosage unit forms of HMG-Co-A reductase inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 120 mg, preferably, when using fluvastatin, for example, 20 mg, 40 mg or 80 mg (equivalent to the free acid) of fluvastatin, for example, administered once a day.

In case of ACE inhibitors, preferred dosage unit forms of ACE inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 20 mg, preferably 5 mg, 10 mg, 20 mg or 40 mg, of benazepril; from about 6.5 mg to 100 mg, preferably 6.25 mg, 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg, of captopril; from about 2.5 mg to about 20 mg, preferably 2.5 mg, 5 mg, 10 mg or 20 mg, of enalapril; from about 10 mg to about 20 mg, preferably 10 mg or 20 mg, of fosinopril; from about 2.5 mg to about 4 mg, preferably 2 mg or 4 mg, of perindopril; from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of quinapril; or from about 1.25 mg to about 5 mg, preferably 1.25 mg, 2.5 mg, or 5 mg, of ramipril. Preferred is t.i.d. administration.

Valsartan, as a representative of the class of AT₁-receptor antagonists, is supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 mg to about 320 mg, of valsartan which may be administered to patients, preferably from about 80 mg to about 320 mg. The application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, valsartan is applied twice a day with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening. Preferred is b.i.d. administration.

In case of SSRIs, preferred dosage unit forms are, for example, tablets or capsules comprising e.g. from about 20 mg to about 200 mg, administered once a day.


In case of PDE5, preferred dosage unit forms are, for example, tablets or capsules comprising e.g. from about 25 mg to about 200 mg, per dose, with 3-isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3, 7-dihydro-purine-2,6-dione being administered in a dose of about 100 mg to about 200 mg.

Examples of formulations of active ingredients of the present inventions are disclosed in WO 01/76573 and WO 01/76574, respectively, the contents of which being incorporated by reference herewith.

What is claimed is

1. A pharmaceutical composition, comprising
 - (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and
 - (b) at least one active ingredient selected from the group consisting of
 - (i) an anti-diabetic agent;
 - (ii) HMG-Co-A reductase inhibitors;
 - (iii) an anti-hypertensive agent; and
 - (v) a serotonin reuptake inhibitor (SSRI)
 or, in each case, a pharmaceutically acceptable salt thereof;
 and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition according to claim 1 wherein PDE 5 inhibitor is a compound of formula



in free or salt form, where

- R^1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio,
 R^2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino,
 R^3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio,
 R^4 is hydrogen or alkyl,
 R^5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula $-N(R^6)R^7$, aryl

optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms attached through a ring carbon atom to the indicated carbon atom, and

R⁶ and R⁷ are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R⁶ and R⁷ is hydrogen and the other is acyl, or R⁶ and R⁷ together with the nitrogen atom to which they are attached denote a 5- or 6- membered heterocyclyl group.

3. The pharmaceutical composition of claim 2 wherein the PDE 5 inhibitor is 3-isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3, 7-dihydro-purine-2,6-dione.

4. The pharmaceutical composition of claim 1 wherein the anti-diabetic agent is selected from the group consisting of insulin secretion enhancers, insulin sensitivity enhancers, insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), antidiabetic non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT); compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK); pyruvate dehydrogenase kinase (PDHK) inhibitors; inhibitors of gastric emptying; insulin; inhibitors of GSK-3; retinoid X receptor (RXR) agonists; agonists of Beta-3 AR; agonists of uncoupling proteins (UCPs); non-glitazone type PPAR γ agonists; dual PPAR γ / PPAR α agonists; antidiabetic vanadium containing compounds; incretin hormones, like glucagon-like peptide-1 (GLP-1) and GLP-1 agonists; β -cell imidazoline receptor antagonists; miglitol; and α_2 -adrenergic antagonists.

5. The pharmaceutical composition of claim 1 wherein the HMG-Co-A reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, pitavastatin, lovastatin, pravastatin, rosuvastatin and simvastatin.

6. The pharmaceutical composition of claim 1 wherein the anti-hypertensive agent is selected from the group consisting of ACE inhibitors, AT1 receptor antagonists, adrenergic blockers, diuretics, neutral endo-peptidases inhibitors, renin inhibitors, endothelin converting enzymes inhibitors, endothelin receptor antagonists, adrenergic stimulants, alpha/beta adrenergic blockers beta adrenergic blocking agents, calcium channel blockers, diuretics, rauwolfia derivatives and vasodilators.

7. The pharmaceutical composition of claim 1 wherein the SSRI is selected from the group consisting of fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram, venlafaxine, cericlamine, duloxetine, milnacipran, nefazodone and cyanodothiepin.
8. A method for the prevention, delay of progression or treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, chronic and acute renal failure, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a warm-blooded mammal in need thereof.
9. The method of claim 8, wherein sexual dysfunction is male erectile dysfunction.
10. A pharmaceutical composition according to claim 1 for use in a method according to claim 8.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/028730 A3

(51) International Patent Classification⁷: **A61K 31/505**,
31/425, A61P 43/00 // (A61K 31/505, 31:425)

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP02/10826

(22) International Filing Date:
26 September 2002 (26.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/325,485 27 September 2001 (27.09.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

Published:
— with international search report

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).


(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(88) Date of publication of the international search report:
4 September 2003

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **COHEN, David, Saul** [US/US]; 98 Primrose Drive, New Providence, NJ 07974 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/028730 A3

(54) Title: PHARMACEUTICAL COMBINATIONS OF PDE-V INHIBITORS AND OTHER AGENTS

(57) Abstract: The present invention relates to a pharmaceutical composition, comprising (a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A reductase inhibitors; (iii) an anti-hypertensive agent; and (iv) a serotonin reuptake inhibitor (SSRI) or, in each case, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/10826

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/505 A61K31/425 A61P43/00 //(A61K31/505,31:425)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 198 44 162 A (WILL GOTTFRIED ;DUNZENDORFER UDO (DE)) 30 March 2000 (2000-03-30) abstract page 2, line 10 - line 13 claims 1-16 ---	1-4,8-10
A	WO 99 30697 A (WYLLIE MICHAEL GRANT ;PFIZER PROD INC (US)) 24 June 1999 (1999-06-24) abstract page 1, line 3 - line 7 page 4, line 2 - line 9 claims 1-125 --- -/--	1-4,8-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

28 January 2003

Date of mailing of the international search report

10 7. 05. 03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patantaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/10826

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 54774 A (PENTECH PHARMACEUTICALS INC) 21 September 2000 (2000-09-21). abstract page 1, line 3 - line 7 page 7, line 17 - line 28 claims 1-20 ---	1-4,8-10
P,X	WO 02 13798 A (KOPPIKER NANDAN PARMANAND ;PFIZER LTD (GB); PFIZER (US); FRYBURG D) 21 February 2002 (2002-02-21) abstract page 1, line 3 - line 5 page 27, line 13 -page 34, line 29 claims 1-63 ---	1-4,8-10
P,X	WO 02 060422 A (KOPPIKER NANDAN PARMANAND ;PFIZER LTD (GB); PFIZER (US); FRYBURG D) 8 August 2002 (2002-08-08) abstract page 12, line 18 -page 19, line 15 claims 1-7 -----	1-4,8-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/10826

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 8 and 9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1, 4, 8-10 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3 (partially), 4, 8-10 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box I.2

Claims Nos.: 1, 4, 8-10 (partially)

Present claims 1, 4 and 8-10 relate to a product/method defined by references to desirable characteristics or properties, namely:

*****[identify the characteristic or property]*****

The claims cover all products/methods having this characteristic or property, whereas the application provides support within the meaning of Art. 6 PCT and/or disclosure within the meaning of Art. 5 PCT for only a very limited number of such product/methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the products/methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

It is furthermore noted that the application contains not a single example of the effects of combination therapy, either from in vitro or in vivo tests, and the application is furthermore deemed to lack support within the meaning of Art. 6 PCT and/or disclosure within the meaning of Art. 5 PCT.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/methods relating to combinations of the PDE-V inhibitors as defined in claims 2 and 3 in combination with the insulin secretion inhibitor repaglinide, as disclosed on p.33, 4th full paragraph.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3 (partially), 4, 8-10 (partially)

Combinations of PDE-V inhibitors and anti-diabetic agents.

2. Claims: 1-3 (partially), 5, 8-10 (partially)

Combinations of PDE-V inhibitors and HMG-Co-A reductase inhibitors.

3. Claims: 1-3 (partially), 6, 8-10 (partially)

Combinations of PDE-V inhibitors and anti-hypertensive agents.

4. Claims: 1-3 (partially), 7, 8-10 (partially)

Combinations of PDE-V inhibitors and SSRIs.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/10826

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19844162	A	30-03-2000	DE 19844162 A1	30-03-2000
			AT 220909 T	15-08-2002
			DE 59902102 D1	29-08-2002
			DK 995441 T3	28-10-2002
			EP 0995441 A2	26-04-2000
WO 9930697	A	24-06-1999	AP 915 A	18-12-2000
			AU 9455898 A	05-07-1999
			BG 104528 A	28-02-2001
			BR 9813699 A	10-10-2000
			CA 2314993 A1	24-06-1999
			CN 1282248 T	31-01-2001
			CZ 20002199 A3	17-10-2001
			EP 1037616 A2	27-09-2000
			HR 20000407 A1	31-10-2000
			HU 0100705 A2	28-08-2001
			WO 9930697 A2	24-06-1999
			JP 2002508315 T	19-03-2002
			NO 20003065 A	15-08-2000
			NZ 504487 A	26-11-2002
			PL 341575 A1	23-04-2001
			SK 8782000 A3	05-03-2002
			TR 200001733 T2	21-11-2000
			ZA 9811507 A	19-06-2000
WO 0054774	A	21-09-2000	US 6087362 A	11-07-2000
			AU 3744500 A	04-10-2000
			BR 0009016 A	16-04-2002
			CA 2367605 A1	21-09-2000
			CN 1350454 T	22-05-2002
			CZ 20013344 A3	14-08-2002
			EP 1173178 A1	23-01-2002
			HU 0200549 A2	29-07-2002
			JP 2002539163 T	19-11-2002
			NO 20014519 A	25-10-2001
			PL 350313 A1	02-12-2002
			WO 0054774 A1	21-09-2000
WO 0213798	A	21-02-2002	AU 7660701 A	25-02-2002
			WO 0213798 A2	21-02-2002
			US 2002165237 A1	07-11-2002
			WO 02060422 A2	08-08-2002
			US 2002143015 A1	03-10-2002
WO 02060422	A	08-08-2002	AU 7660701 A	25-02-2002
			WO 0213798 A2	21-02-2002
			WO 02060422 A2	08-08-2002
			US 2002143015 A1	03-10-2002
			US 2002165237 A1	07-11-2002

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)